-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on CytomX Therapeutics, Raises Price Target to $15

Benzinga·03/18/2026 13:09:08
Listen to the news
Guggenheim analyst Michael Schmidt maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and raises the price target from $10 to $15.